利生奇珠单抗在银屑病关节炎GRAPPA各领域中的疗效:3期KEEPsAKE 1和2研究患者汇总分析
该事后分析主要使用3期KEEPsAKE 1试验数据并汇总KEEPsAKE 2预设结局,评估利生奇珠单抗治疗100周在银屑病关节炎各GRAPPA领域及 IBD、葡萄膜炎中的疗效;结果显示各领域均有效,第100周42.4%达低疾病活动度、62.9%达疼痛最小临床重要差异,IBD和葡萄膜炎新发或 flare 率低。
要点
- 利生奇珠单抗在肿胀和压痛关节数、附着点炎、指趾炎、皮肤和甲、中轴病变各GRAPPA领域至100周均显示疗效。
- KEEPsAKE 1第100周42.4%达银屑病关节炎疾病活动度低疾病活动度,62.9%达疼痛最小临床重要差异。
- IBD和葡萄膜炎新发或 flare 率低,基于至100周的不良事件评估。
核心结论
- 利生奇珠单抗治疗可为银屑病关节炎所有GRAPPA疾病领域及相关疾病提供体征和症状的持久改善。
研究设计与样本
- 此项事后分析主要使用3期KEEPsAKE 1试验的成人银屑病关节炎患者数据,并将KEEPsAKE 2数据汇总用于预设结局。
- 评估利生奇珠单抗在100周治疗(约2年)内对GRAPPA认可领域及银屑病关节炎相关疾病(IBD和葡萄膜炎)的疗效。
- 统计方法包括分类变量采用无应答填补(按观察值填补),连续变量采用重复测量混合效应模型(包括所有访视的按观察值测量)。
- 银屑病关节炎相关疾病通过至100周的不良事件进行评估。
主要发现
- KEEPsAKE 1中412/483(85.3%)、KEEPsAKE 2中181/224(80.8%)随机接受利生奇珠单抗的患者完成至第100周的治疗。
- 利生奇珠单抗在至100周的所有GRAPPA定义领域显示疗效,包括肿胀和压痛关节计数、附着点炎、指趾炎、皮肤和甲结局及中轴病变。
- KEEPsAKE 1第100周42.4%的患者达到银屑病关节炎疾病活动度低疾病活动度,62.9%达到疼痛最小临床重要差异。
- IBD和葡萄膜炎的新发或 flare 率低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA). METHODS: This post hoc analysis primarily used data from the phase 3 KEEPsAKE 1 trial of adult patients with PsA, with data from KEEPsAKE 2 pooled for prespecified outcomes. Outcomes measuring risankizumab efficacy across key GRAPPA-recognised domains of PsA (peripheral arthritis, enthesitis, dactylitis, skin and nail psoriasis, axial disease) and PsA-related conditions such as inflammatory bowel disease (IBD) and uveitis were assessed over 100 weeks of treatment (~2 years). Statistical approaches included non-responder imputation (as-observed with imputation) for categorical variables and mixed-effect model for repeated measures for continuous variables including as-observed measurements at all visits. PsA-related conditions were evaluated via adverse events through 100 weeks. RESULTS: Overall, in KEEPsAKE 1 and KEEPsAKE 2, 412/483 (85.3%) and 181/224 (80.8%) of patients randomised to risankizumab completed treatment to week 100. Risankizumab demonstrated efficacy across all GRAPPA-defined domains through 100 weeks, including swollen and tender joint counts, enthesitis, dactylitis, skin and nail outcomes, and axial disease. In KEEPsAKE 1, 42.4% of patients had achieved a Disease Activity in Psoriatic Arthritis measurement of low disease activity and 62.9% had reached a minimal clinically important difference in pain at week 100. Rates of new onset or flare of IBD and uveitis were low. CONCLUSIONS: Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all GRAPPA disease domains and related conditions.
引用
- Coates LC, Blanco R, Behrens F, et al. Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies. RMD Open. 2025. PMID: 40854810. doi:10.1136/rmdopen-2025-005522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。